Articles From: Global Cash Access Holdings, Inc. Announces Proposed Private Offering of $350.0 Million of Senior Secured Notes and $350.0 Million of Senior Unsecured Notes to PDL BIOPHARMA 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against PDL BioPharma, Inc. -- PDLI


Hudson Pacific Properties, Inc. (the “Company”) (NYSE: HPP) announced that the Company’s Board of Directors has declared a quarterly dividend on its common stock of $0.125 per share for the fourth quarter of 2014.
Sign-up for Hudson Pacific Properties, Inc. Declares Fourth Quarter 2014 Dividends investment picks
CHARLOTTE, N.C. , Dec.
Sign-up for CCG Comments on Director Nominations investment picks
SPARTANBURG, S.C., Dec.
Sign-up for Denny's Corporation to Participate in Upcoming Investor Conference investment picks
TUCSON, Ariz., Dec.
Sign-up for Sinfonia HealthCare Acquires New Orleans Based Mental Health Agency investment picks
ATLANTA , Dec.
Sign-up for Delta Taps Seven More Craft Brews for In-Flight Offering investment picks
HAIFA, Israel , November 17, 2014 /PRNewswire/ -- Elbit Systems Ltd.
Sign-up for Elbit Systems MUSIC™ Self-Protection DIRCM Solution Marks Another Milestone, This Time in Germany: Elbit Systems Awarded a Contract to Supply DIRCM Systems for the German Air Force's New A400M Aircraft investment picks
Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced the completion of a method development project conducted in partnership with GlaxoSmithKline plc (GSK) to evaluate the impact of unifying mobile health (mHealth) devices with cloud-based technologies in a clinical trial setting.
Sign-up for Medidata Collaborates with GlaxoSmithKline on Mobile Health Initiative to Test Novel Technology for Clinical Trial Optimization investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1159279&ProfileId=051205&sourceType=1 BAIE VERTE, NL --
Sign-up for Rambler and Maritime Agree to Evaluate the Viability of Restarting the Past Producing Hammerdown Gold Mine investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1159289&ProfileId=051205&sourceType=1 ABERDEENSHIRE, UNITED KINGDOM --
Sign-up for Xcite Energy Limited Memorandum of Understanding With China Oilfield Services Limited investment picks
SEATTLE , Nov.
Sign-up for CTI BioPharma to Present at the Upcoming Investor Conferences investment picks
AUSTIN, Texas , Nov.
Sign-up for Hanger Postpones Release of Third Quarter 2014 Financial Results investment picks
AstraZeneca (NYSE: AZN) today presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with xanthine oxidase (XO) inhibitor allopurinol.
Sign-up for AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting investment picks
Months of dedication and hard work in science, technology, engineering and mathematics (STEM) paid off tonight for three students named National Finalists in the Siemens Competition in Math, Science & Technology, the nation’s premier research competition for high school students.
Sign-up for Arizona and New Mexico High School Scientists Win Regional Siemens Competition at the University of Texas at Austin for Research on Intrinsically Disordered Proteins for Drug Discovery and Computational Models of Tree Growth investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced preliminary results from a phase 1 investigator-sponsored trial (IST) evaluating the safety and activity of XL888, an Exelixis-discovered small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), in combination with vemurafenib in patients with unresectable stage III/IV BRAF V600 mutation-positive melanoma.
Sign-up for Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib investment picks
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers presented data from clinical trials of Soliris ® (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS), as well as an update from the Global aHUS Registry, at Kidney Week 2014, the annual meeting of the American Society of Nephrology, in Philadelphia.
Sign-up for Longer-term Outcome Data from the Largest Prospective Trial of Soliris® (eculizumab) in aHUS Underscore the Effectiveness of Ongoing Soliris Treatment investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Global Cash Access Holdings, Inc. Announces Proposed Private Offering of $350.0 Million of Senior Secured Notes and $350.0 Million of Senior Unsecured Notes to PDL BIOPHARMA 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against PDL BioPharma, Inc. -- PDLI
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent